🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CONGRESS | #ASH24 | POSTER Fausto A Rios-Olais Fausto A. Rios Olais INCMNSZ shares findings from a study examining the relationship between metabolic complications and asparaginase-containing pediatric-inspired regimens in adult patients with ALL (N = 92). Liver steatosis was associated

1/ 📢 Let’s dive into a crucial topic in #Hematology: How do adult regimens compare with pediatric-inspired regimens (PIRs) for Philadelphia-negative ALL? Our study from Mexico offers some insights #ALL Roberta Demichelis Fausto A. Rios Olais Juan Rangel MD Analy Mora onlinelibrary.wiley.com/doi/10.1111/ej…

El INCMNSZ felicita a la Dra. María Roberta Demichelis Gómez por su nombramiento como Jefa del Departamento de Hematología y Oncología.

🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉 Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario. 🔗 docs.google.com/forms/d/e/1FAI… Tu aporte será clave para mejorar la atención de LLA en la región.

Excited to share our new study on non-cirrhotic portal vein thrombosis in Hispanics! -⬆️ % of antiphospholipid syndrome -Substantial variceal 🩸 risk -Anticoagulation was not associated with ⬆️ risk of 🩸 Check it out: pubmed.ncbi.nlm.nih.gov/39993595/

📢 Body composition in adult ALL 📊 In our study published at ESPEN, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections. clinicalnutritionespen.com/article/S2405-… Roberta Demichelis Fernando Gil-Lopez Analy Mora Jessica Zalapa

New Article! 🚨 We just published a deep dive into Portal Vein Thrombosis in Patients Without Cirrhosis – exploring real-world treatment strategies and practical approaches. 🩺💡 Fausto A. Rios Olais Lydia Mercado Check it out: mdpi.com/2075-4418/15/6… #Hepatology #Thrombosis

Thanks to all the professors and attendees who joined us at this first hematology congress at INCMNSZ Wendy Stock G Garcia-Manero Keith W Pratz MD Alejandro Lazo Ruben Niesvizky Jorge Cortes MD Enrique Soto Carmelo Gurnari Juan Manuel Mejía Paty Navarrete Zuilma Vásquez Juan Rangel MD

📝 A retrospective analysis published in Leukemia & Lymphoma found that the median OS was not reached in patients with Ph+ B-ALL receiving rituximab vs 14 months in those who did not. More news: lymphoblastic-hub.com #allsm #leusm #MedNews #MedEd

Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%. Read the full review “Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress”

🎯 Bottom line: Allo-HSCT offers curative potential in MDS/MPN overlap neoplasms. PTCy (± ATG) appears to improve survival outcomes without added relapse risk. 👉 Further multicenter studies needed. 📖 Full study: doi.org/10.1111/ejh.14… #HemeTwitter #AlloHSCT #GVHD

📊 How many patients with lymphoma or myeloma in the US actually benefit from bispecific antibodies? In our Blood Advances letter, we estimate eligibility and response under current FDA labels—and why real-world benefit may be limited. Talal Hilal 🩺 ashpublications.org/bloodadvances/…